Evidence map›Paper›PMID 38871216›Full record

ArticleThe ocular surface2024

Calcium-sensing receptor (CaSR) modulates ocular surface chloride transport and its inhibition promotes ocular surface hydration.

Neel D Pasricha, Ethan S Lindgren, Rongshan Yan, Yien-Ming Kuo, Matilda Chan, Alan S Verkman, Tifany Chu, Pattareeya Yottasan, Livia de Souza Goncalves, Onur Cil

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The ocular surface, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Exploring multiple drug actions of a CaNaunyn-Schmiedeberg's archives of pharmacology · 2026
    Review
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Neel D PasrichaDepartment of Ophthalmology, University of California, San Francisco, United States; Francis I. Proctor Foundation, University of California, San Francisco, United States.
Ethan S LindgrenDepartment of Ophthalmology, University of California, San Francisco, United States.
Rongshan YanDepartment of Ophthalmology, University of California, San Francisco, United States.
Yien-Ming KuoDepartment of Ophthalmology, University of California, San Francisco, United States.
Matilda ChanDepartment of Ophthalmology, University of California, San Francisco, United States; Francis I. Proctor Foundation, University of California, San Francisco, United States.
Alan S VerkmanDepartment of Medicine and Physiology, University of California, San Francisco, United States.
Tifany ChuDepartment of Pediatrics, University of California, San Francisco, United States.
Pattareeya YottasanDepartment of Pediatrics, University of California, San Francisco, United States.
Livia de Souza GoncalvesDepartment of Pediatrics, University of California, San Francisco, United States.
Onur CilDepartment of Pediatrics, University of California, San Francisco, United States. Electronic address: onur.cil@ucsf.edu.

Funding

Rapid-Prototyping and Design CoreP30EY002162 · NEI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI LAMBA, DEEPAK ASHOK · 1985 to 2024
$16.8M
UCSF-Proctor Clinician Vision Scholars K12 ProgramK12EY031372 · NEI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI THOMAS M LIETMAN, Yvonne Ou · 2020 to 2026
$3.9M
Vision Bioinformatics and ComputationP30EY037668 · NEI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Erik M Ullian · 2025 to 2026
$2.0M
SLC26A3 (DRA) Inhibitors for Treatment of Hyperoxaluria and NephrolithiasisR01DK126070 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI CIL, ONUR · 2020 to 2024
$1.6M
Roles of CaSR in ocular surface health and diseaseR01EY036139 · NEI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Onur Cil · 2024 to 2026
$1.2M
Human Ocular Surface ElectrophysiologyK08EY033859 · NEI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Neel Dave Pasricha · 2023 to 2026
$877k
NEI NIH HHS K08 EY033859NEI NIH HHS K12 EY031372NEI NIH HHS P30 EY002162NEI NIH HHS P30 EY037668NEI NIH HHS R01 EY036139NIDDK NIH HHS R01 DK126070
6 · The paper itself

Abstract

purposeOcular surface hydration is critical for eye health and its impairment can lead to dry eye disease. Extracellular calcium-sensing receptor (CaSR) is regulator of ion transport in epithelial cells expressing cystic fibrosis transmembrane conductance regulator (CFTR) Cl

methodsCaSR immunostaining was performed in mouse and human cornea and conjunctiva. Ocular surface potential difference (OSPD) and tear fluid volume measurements were performed in mice with topically applied cinacalcet (CaSR activator) and NPS-2143 (CaSR inhibitor).

resultsCaSR is expressed in corneal and conjunctival epithelia of mice and humans. Topically administered CaSR activator cinacalcet inhibits cAMP agonist forskolin-induced Cl

conclusionsCaSR is a key regulator of ocular surface ion transport and CaSR inhibition promotes Cl

Indexed as

ConjunctivaReceptors, Calcium-SensingTearsAnimalsChloridesCinacalcetCorneaCystic Fibrosis Transmembrane Conductance RegulatorDry Eye SyndromesFemaleHumansIon TransportMaleMiceMice, Inbred C57BLNaphthalenesChloridesCinacalcetCystic Fibrosis Transmembrane Conductance RegulatorN-(2-hydroxy-3-(2-cyano-3-chlorophenoxy)propyl)-1,1-dimethyl-2-(2-nephthyl)ethylamineNaphthalenesReceptors, Calcium-SensingCalcilyticsCalcimimeticsChloride transportDry eye diseaseTear secretion

Identifiers

PMID38871216
PMCPMC11887457

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.